Sola-Gallego, I. (I.)

Filtering

1991 - 199912010 - 20161

Settings

Author search.filters.isAuthorOfPublication.18a07abd-c390-439f-93d9-ca6c0e212abe

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Adenoma de las glándulas de Brunner
    (The Spanish Society of Digestive Pathology, 1991) Contreras-Mejuto, F. (F.); Robledo-Arribas, M. (M.); Pardo-Mindan, F.J. (Francisco Javier); Sola-Gallego, I. (I.)
    El adenoma de glándulas de Brunner representa el 10% de los tumores benignos del duodeno. Su localización más frecuente es en la primera porción del duodeno y es extremadamente raro por debajo de la ampolla de Vater. Presentamos dos casos, uno de ellos asociado a adenocarcinoma de la ampolla de Vater. Esta asociación no está descrita en la literatura. No existe ningún caso en que se demuestre una transformación de adenoma a adenocarcinoma. Para estas lesiones nodulares solitarias es más correcto el término de adenoma que el de hiperplasia, debiéndose reservar este último para las proliferaciones más difusas.
  • Thumbnail Image
    Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation
    (Elsevier, 2016) Cambeiro, M. (Mauricio); Martinez-Regueira, F. (Fernando); Rodriguez-Spiteri, N. (Natalia); Olartecoechea, B. (Begoña); Pina-Insausti, L. (Luis); Elizalde, A. (Arlette); Idoate, M.A. (Miguel Ángel); Sola-Gallego, I. (I.); Santisteban, M. (Marta); Aramendia, J.M. (José Manuel); Aristu-Mendioroz, J.J. (José Javier); Arbea-Moreno, L. (Leire); Moreno-Jimenez, M. (Marta); Valtueña-Peydró, G. (Germán); Martinez-Monge, R. (Rafael)
    PURPOSE: To assess the safety, feasibility, and efficacy of free-hand intraoperative multicatheter breast implant (FHIOMBI) and perioperative high-dose-rate brachytherapy (PHDRBT) in early breast cancer. METHODS ANDMATERIALS: Patientswithearlybreastcancercandidates forbreast conservative surgery (BCS) were prospectively enrolled. Patients suitable for accelerated partial breast irradiation (APBI) (low or intermediate risk according GEC-ESTRO criteria) received PHDRBT (3.4 Gy BID 10in5days).PatientsnotsuitableforAPBI(highriskpatientsaccordingGEC-ESTROcriteria) received PHDRBT boost (3.4 Gy BID 4 in 2 days) followed by whole breast irradiation. RESULTS: From June 2007 to November 2014, 119 patients were treated and 122 FHIOMBI procedures were performed. Median duration of FHIOMBI was 25 minutes. A median of eight catheters (range, 4e14) were used. No severe intraoperative complications were observed. Severe early postoperative complications (bleeding) were documented in 2 patients (1.6%), wound healing complications in 3 (2.4%), and infection (mastitis or abscess) in 2 (1.6%). PHDRBT was delivered as APBI in 88 cases (72.1%) and as a boost in 34 (27.8%). The median clinical target volume T was40.8cc(range, 12.3e160.5); median D90was3.32Gy(range,3.11e3.85);mediandosehomogeneityindexwas0.72(range,0.48e0.82).Withamedianfollowupof38.4months(range,8.7e98.7)no local, elsewhere, or regional relapses were observed; there was only one distant failure in PHDRBT boost. No major (acute or late) RTOG grade 3 or higher were documented in any of the 119 patients treated with PHDRBT. Cosmetic outcome in APBI patients was excellent orgood in (87.0%) and fair or poor in (11.9%) while in boost patients was excellent or good in (76.4%) and fair in (23.5%). CONCLUSION: The FHIOMBI-PHDRBT program does not add complications to conservative surgery. It allows precise selection of APBI patients and offers excellent results in disease control and cosmetics. It also offers logistic advantages because it dramatically shortens the time of local treatment and avoids further invasive procedures.